Welcome

Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and
others concerned about HIV/AIDS. Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the
conversation yourself by registering on the left side of this page.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive
and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a
username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own
physician.

All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators
of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please
provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are
true and correct to their knowledge.

Author
Topic: HIV antibody that could lead to a vaccine for the virus--UChicago’s Argonne (Read 963 times)

Cutting-edge research at UChicago’s Argonne National Laboratory is a potential first step to the development of an HIV vaccine. The research, focused on mapping the development of the CH103 antibody, was a collaborative effort, bringing together analysis conducted at Los Alamos National Laboratory and experiments conducted at Argonne.The natural antibody CH103 is able to neutralize multiple strains of HIV, making it a uniquely effective and adaptive virus killer. By examining the formation and evolution of the antibody in relation to the virus, scientists can better understand how to reproduce the antibody in a vaccine.“HIV–1 is a master of disguise, and it is very difficult for the human immune system to make antibodies that effectively neutralize diverse HIV–1 isolates. “The CH103 antibody is pretty good as a neutralizer,” said Doctor Peter Kwong (A.B. ’85, S.M. ’85), who led Argonne’s efforts in the research. Kwong works in the Structural Biology section of the National Institute of Health’s Vaccine Research Center.In order to conduct the study, the researchers acquired samples from an HIV–positive donor starting from the time of infection, allowing the group to obtain information about the progress of the virus and the evolution of the antibody.Today, Kwong’s research group studies the conditions, on an atomic level, that trigger the creation of CH103 antibodies.Understanding the development of the CH103 antibody is a significant first step toward developing an HIV vaccine, though the complete creation of a vaccine is probably years down the road.